Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 65, Issue 1, Pages S2-S21 (October 2016)
Volume 50, Issue 4, Pages (April 2009)
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Tiny RNA with great effects: miR-155 in alcoholic liver disease
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Hepatic CD141+IFNλ+ DC subset: One against all?
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Mirjam B. Zeisel, Isabel Fofana, Samira Fafi-Kremer, Thomas F. Baumert 
Volume 51, Issue 6, Pages (December 2009)
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 42, Issue 1, Pages (January 2005)
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Determinants of hepatic effector CD8+ T cell dynamics
Hepatitis B and C virus-related carcinogenesis
Virological tools to diagnose and monitor hepatitis C virus infection
Volume 66, Issue 1, Pages 1-4 (January 2017)
Heidi Barth, Eric Robinet, T. Jake Liang, Thomas F. Baumert 
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Hepatitis C virus entry and glucocorticosteroids
Living donor liver transplantation: is the hype over?
Thomas F. Baumert, Catherine Fauvelle, Diana Y. Chen, Georg M. Lauer 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 68, Issue 3, Pages (March 2018)
A dive into the complexity of type I interferon antiviral functions
RNAi – A powerful tool to unravel hepatitis C virus–host interactions within the infectious life cycle  Joachim Lupberger, Laurent Brino, Thomas F. Baumert 
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Daniel J. Felmlee, Thomas F. Baumert  Journal of Hepatology 
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Host-targeting agents for prevention and treatment of chronic hepatitis C – Perspectives and challenges  Mirjam B. Zeisel, Joachim Lupberger, Isabel Fofana,
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Hepatitis B and C virus-related carcinogenesis
Volume 50, Issue 4, Pages (April 2009)
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Fei Xiao, Jane A. McKeating, Thomas F. Baumert  Journal of Hepatology 
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
HCV targeting of patients with cirrhosis
Immunological techniques in viral hepatitis
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
Jean Dubuisson, François-Loïc Cosset  Journal of Hepatology 
HCV animal models and liver disease
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Eric Robinet, Thomas F. Baumert  Journal of Hepatology 
Genetics of hepatocellular carcinoma: The next generation
Philippe Metz, Antje Reuter, Silke Bender, Ralf Bartenschlager 
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
Volume 64, Issue 6, Pages (June 2016)
Presentation transcript:

Genetically humanized mice recapitulate the entire hepatitis C virus life cycle  Laurent Mailly, Mirjam B. Zeisel, Thomas F. Baumert  Journal of Hepatology  Volume 60, Issue 3, Pages 671-673 (March 2014) DOI: 10.1016/j.jhep.2013.10.005 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 A novel mouse model recapitulating the entire HCV lifecycle based on Dorner et al. [10]. Plasmid vectors encoding the four main human HCV entry factors (4hEF) CD81, SR-BI, CLDN1, and OCLN under the control of the mouse albumin promoter were used to create transgenic animals susceptible to HCVcc entry but not permissive to robust viral replication. Crossing 4hEF mice with mice knock-out for defined genes involved in innate immunity (Stat1−/−, Irf1−/−, Irf7−/−, Ifnar1−/−) resulted in transgenic mice that can be efficiently infected by HCVcc. These mice were characterized by a viremia of approximately 2months and circulating infectious virions with a TCID50 of approximately 102/ml. Journal of Hepatology 2014 60, 671-673DOI: (10.1016/j.jhep.2013.10.005) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions